The estimated Net Worth of Jami K Nachtsheim is at least $463 millier dollars as of 10 May 2024. Ms. Nachtsheim owns over 2,000 units of Cerus stock worth over $222,142 and over the last 20 years she sold CERS stock worth over $13,267. In addition, she makes $227,260 as Independent Director at Cerus.
Jami has made over 14 trades of the Cerus stock since 2018, according to the Form 4 filled with the SEC. Most recently she bought 2,000 units of CERS stock worth $3,580 on 10 May 2024.
The largest trade she's ever made was exercising 13,228 units of Cerus stock on 1 June 2021 worth over $27,117. On average, Jami trades about 948 units every 58 days since 2004. As of 10 May 2024 she still owns at least 108,362 units of Cerus stock.
You can see the complete history of Ms. Nachtsheim stock trades at the bottom of the page.
Jami Dover Nachtsheim serves as Independent Director of the Company. Ms. Nachtsheim served in a variety of positions with Intel Corporation from 1980 until her retirement in 2000, most recently as the Corporate Vice President of the Sales and Marketing Group and Director of Worldwide Marketing. Ms. Nachtsheim served on the board of directors of FEI Company from March 2010 until its acquisition by Thermo Fisher Scientific Inc. in September 2016. Ms. Nachtsheim also served on the board of directors of Affymetrix, Inc. from May 2009, and as Chairman starting January 2015, until its acquisition by Thermo Fisher Scientific Inc. in March 2016. Ms. Nachtsheim currently serves on the board of directors of Intuitive Surgical, Inc. and has since April 2017. Ms. Nachtsheim holds a B.S. in Business Management from Arizona State University.
As the Independent Director of Cerus, the total compensation of Jami Nachtsheim at Cerus is $227,260. There are 7 executives at Cerus getting paid more, with William Greenman having the highest compensation of $3,270,180.
Jami Nachtsheim is 61, she's been the Independent Director of Cerus since 2019. There are 5 older and 8 younger executives at Cerus. The oldest executive at Cerus Corp. is Laurence Corash, 76, who is the Chief Scientific Officer.
Jami's mailing address filed with the SEC is 1020, Kifer Road, Sunnyvale, Santa Clara County, California, 95086, United States.
Over the last 21 years, insiders at Cerus have traded over $5,083,598 worth of Cerus stock and bought 1,382,745 units worth $4,903,526 . The most active insiders traders include William Mariner Greenman, Laurence M Corash et Bruce C Cozadd. On average, Cerus executives and independent directors trade stock every 33 days with the average trade being worth of $90,805. The most recent stock trade was executed by Kevin Dennis Green on 3 September 2024, trading 82,657 units of CERS stock currently worth $178,539.
cerus corporation is a biomedical products company focused on commercializing the intercept blood system to enhance blood safety. the intercept system is designed to reduce the risk of transfusion-transmitted diseases by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood. the nucleic acid targeting mechanism of action enables intercept treatment to inactivate established transfusion threats, such as hepatitis b and c, hiv, west nile virus and bacteria, and is designed to inactivate emerging pathogens such as influenza, malaria and dengue. cerus currently markets and sells the intercept blood system for both platelets and plasma in europe, russia, the middle east and selected countries in other regions around the world. the intercept red blood cell system is in clinical development.
Cerus executives and other stock owners filed with the SEC include: